Transformative first-in-class ADC Therapies For Cancers With High Unmet Medical Need
Adcendo ApS is a Copenhagen-based, near clinical-stage biotech company dedicated to developing highly differentiated first-in-class (FIC) antibody-drug conjugates (ADCs) for the treatment of underserved cancers.
Latest news
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline
Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support the advancement of...
Adcendo to Participate in Expert ADC Panel Debate at BIO-Europe 2024
Copenhagen, Denmark, October 29th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announces that its CEO, Michael Pehl will join fellow...
Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple STS subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety,...
Our Pipeline
Our pipeline of four First-in-Class ADCs combines deep understanding of novel targets with optimized ADC technology for selected solid tumor indications.
What are ADCs?
Antibody-drug conjugates (ADCs) represent an an exciting new drug modality, directing anticancer therapeutics to malignant cells overexpressing particular surface antigens.
10+ ADCs are approved for clinical use, with many more in clinical testing for solid tumors as well as hematologic malignancies.
Our investors
In November 2024, Adcendo completed a Series B financing round through an international syndicate of leading life science and biotech investors, raising $135 million to advance, broaden, and accelerate the development of our first-in-class ADC pipeline.
Including our series A financing round and extensions, the Company has raised a total of $240 million to date.
